Avalyn Pharma Reports Phase 1 Data For Inhaled Nintedanib AP02
Avalyn Pharma Inc. published Phase 1 trial data for its inhaled nintedanib AP02, detailing lung-targeted delivery with encouraging safety and lower systemic levels compared to oral nintedanib. The program is advancing to a Phase 2 study, with topline data expected in late 2027.